Roche to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH for US $3.5 billion
On Sept. 17, 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio,…
-
-
GSK to invest $30 billion in R&D and Manufacturing in the U.S. over next 5 years
On Sept. 17, 2025, GSK announced plans to invest $30 billion across the United States in research and…
-
Large-scale DNA study maps 37,000 years of disease history
On Jul. 9, 2025, a research team led by Eske Willerslev, professor at the University of Copenhagen and…
-
Researchers take first steps to creating synthetic human genomes
On Jun. 26, 2025, a team of UK-based scientists announced they are developing technology to create the first…
-
Biotechnology | COVID-19 | Diagnostics | HIV | Infectious Disease | Influenza | Measles | Non-Profit Research | Plague | Polio | Vaccine
UK Report highlights Two Dozen pathogens of greatest risk to public health
On Mar. 25. 2025, the UK Health Security Agency (UKHSA) published its view on the pathogen families that…
-
Artificial Intelligence | Biotechnology | Medical Device | Medicine | Nanotechnology | Neurology | Therapeutics
Rice labs tapped for brain research by UK funding agency with multimillion-dollar awards
On Jan. 21, 2025, Rice University announced that four research groups are part of an inaugural cohort of…
-
Biotechnology | Diagnostics | Disease | Genomics | Neurology | Therapeutics
Study pinpoints depression genes across ethnicities
On Jan. 14, 2025, an international research team led by the University of Edinburgh reported new genetic risk…
-
Tumour DNA in the blood can predict lung cancer outcome
On Jan. 13, 2025, scientists from the Francis Crick Institute, UCL, UCLH and Personalis announced they have found…
-
Genetic cause for main type of hearing loss in children with Down syndrome identified
On Jan. 7, 2025, researchers at the Francis Crick Institute, MRC Harwell Institute and UCL Queen Square Institute…
-
First new treatment for asthma attacks in 50 years
On Nov. 28, 2024, scientists from King’s College London reported that an injection given during some asthma and…
-
AI can predict study results better than human experts
On Nov. 27, 2024, a study led by the University College London reported that large language models, a…
-
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
-
Biotechnology | Disease | FDA | Therapeutics
Swissmedic Authorises CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
-
WHO announced influenza A(H1N2) variant virus infection in the Great Britain and Northern Ireland
On Dec. 1, 2023, the World Health Organization (WHO) announced that the International Health Regulations National Focal Point…
-
Agriculture | Biotechnology | Diagnostics | Infectious Disease | Influenza | Therapeutics | Vaccine | Veterinary
UK Animal and Plant Health Agency reported asymptomatic human detections of influenza A (H5N1)
On Jul. 14, 2023, the UK Animal and Plant Health Agency reported that additional asymptomatic human detections of…
-
BioNTech announced strategic partnership with UK Government to provide up to 10,000 patients with personalized mRNA cancer immunotherapies
On Jan. 5, 2023, BioNTech announced that the Company had signed a Memorandum of Understanding with the Government…
-
Spanish, Italian and French Health Authorities expanded recommendations for use of Novavax COVID-19 vaccine
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
-
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
-
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
-
Sanofi and GSK announced regulatory authorization for COVID-19 vaccine
On Feb. 23, 2022, Sanofi and GSK announced that they planned to submit data from both their booster…
-
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
-
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
-
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
-
DNA from air could revolutionize the way we measure animal biodiversity
On Jan. 6, 2022, two new studies published in the journal Current Biology showed that environmental DNA (eDNA)…
-
Merck and Ridgeback announced U.K. Government to purchase additional 1.75 million courses of molnupiravir
On Dec. 22, 2021, Merck and Ridgeback Biotherapeutics announced that the United Kingdom Government agreed to purchase an…
-
Moderna announced supply agreement with the UK for additional 60 million doses of COVID-19 vaccine in 2022 and 2023
On Dec. 1, 2021, Moderna announced a revised supply agreement with the UK government for up to 60…
-
Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
-
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
-
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
